Somatostatin Analogs as Radiodiagnostic Tools

Herder, Wouter W. de; Lamberts, Steven W. J.

doi:10.1007/s11154-005-5221-3

Cited by 5 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially, 123 I-Tyr3-octreotide was used for SSTR imaging (15), but was soon replaced by 111 In-pentetreotide (16). Several groups have examined the correlation between scintigraphic findings, tumoral SSTR expression (14,17,18), and the clinical/biochemical response to medical therapy (19,20), concluding that SSTR scintigraphy may help identify patients who would benefit from a trial of SSTR ligands; however, these findings have not been reproduced by other workers (21)(22)(23).…”

Section: Sstr Imaging (Supplemental Table 1)mentioning

confidence: 99%

Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas

et al. 2021

View full text Add to dashboard Cite

In most patients with suspected or confirmed pituitary adenomas (PAs), MRI, performed using T1-(with or without gadolinium enhancement) and T2-weighted sequences, provides sufficient information to guide effective clinical decision making. In other patients, additional MR sequences (e.g., gradient recalled echo, fluid-attenuation inversion recovery, MR elastography, or MR angiography) may be deployed to improve adenomadetection, assess tumoral consistency, or aid distinction from other sellar/parasellar lesions (e.g., aneurysm, meningioma). However, there remains a small but important subgroup of patients in whom primary or secondary intervention (e.g., first or redo transsphenoidal surgery, stereotactic radiosurgery) is limited by the inability of MRI to accurately localize the site(s) of de novo, persistent, or recurrent PA. Emerging evidence indicates that hybrid imaging, which combines molecular (e.g. 11 C-methionine PET) and cross-sectional (MRI) modalities, can enable the detection and precise localization of sites of active tumor to guide targeted intervention. This not only increases the likelihood of achieving complete remission with preservation of remaining normal pituitary function but may mitigate the need for long-term (even lifelong) high-cost medical therapies. Here, we review published evidence supporting the use of molecular imaging in the management of PAs, including our own 10-y experience with 11 C-methionine PET.

show abstract

Section: Sstr Imaging (Supplemental Table 1)mentioning

confidence: 99%

Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In several studies an association between the increased 111 Inpentetreotide uptake in the somatotroph pituitary tumor and the inhibition of the pathologic GH secretion by octapeptide somatostatin analogs could be found, whereas others were unable to demonstrate such a relationship [31,[33][34][35][36][37]. Similarly, a positive correlation between the increased 111 In-pentetreotide uptake in TSH-secreting pituitary adenomas and the inhibition of excessive TSH secretion by octreotide has been shown [35,38].…”

Section: Somatostatin Receptor Imaging Of Pituitary Tumorsmentioning

confidence: 99%

“…With regard to 111 In-pentetreotide scintigraphy in patients with sellar and extrasellar tumors it is important to realize that the nonpathologic anterior pituitary gland also takes up 111 In-pentetreotide [31]. Therefore, most studies have been using either a visual scoring system, or cut-off values have been determined for an uptake index calculated from the uptake of radioactivity in the pituitary region of interest (ROI) divided by the uptake in a fixed background ROI.…”

Section: Somatostatin Receptor Imaging Of Pituitary Tumorsmentioning

confidence: 99%

“…111 In-pentetreotide scintigraphy was negative in patients with microprolactinomas and ACTH-secreting pituitary microadenomas [37,39]. 111 Inpentetreotide scintigraphy was positive in patients with infiltrating macroprolactinomas and invasive ACTH-secreting macroadenomas [31,37,39]. 111 In-pentetreotide scintigraphy has been successful for the localization of extrapituitary ACTH-and CRH-secreting tumors and their metastases, especially in those difficult cases in which conventional radiological studies had initially failed to localize the tumors [40][41][42][43][44][45][46][47][48][49][50][51].…”

Section: Somatostatin Receptor Imaging Of Pituitary Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

Somatostatin receptor imaging for neuroendocrine tumors

Herder

Kwekkeboom²,

Feelders

et al. 2006

Pituitary

Self Cite

View full text Add to dashboard Cite

Tumors and metastases that express the somatostatin receptor subtypes sst2 sst3 or sst5 can be visualized in vivo after injection of radiolabeled octapeptide somatostatin analogs, like (111)In-pentetreotide. (111)In-pentetreotide scintigraphy also allows for more accurate staging of the disease by demonstrating tumor sites, which were not shown by conventional imaging. (111)In-pentetreotide scintigraphy may also detect resectable tumors that would have remained unrecognized using conventional radiological imaging techniques; it may prevent surgery with curative intent in those patients whose tumors have metastasized to a greater extend than could be detected with conventional radiological imaging and it may be used to select patients for treatment with the currently available octapeptide somatostatin analogs or with tumor targeted radioactive treatment with radiolabelled somatostatin analogs. (111)In-pentetreotide scintigraphy has also been used to select patients with pituitary tumors for medical treatment with octapeptide analogs, but its clinical usefulness for this purpose seems to be limited. It further allows scar tissue to be differentiated from tumor recurrence after the pituitary surgery or radiotherapy. However, a large variety of lesions in and around the pituitary region also express somatostatin receptors and, therefore, can be visualized by (111)In-pentetreotide scintigraphy.

show abstract

Somatostatin and Somatostatin Receptors

Kumar

Grant

2009

Results and Problems in Cell Differentiation

View full text Add to dashboard Cite

Somatostatin Analogs as Radiodiagnostic Tools

Cited by 5 publications

References 47 publications

Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas

Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas

Somatostatin receptor imaging for neuroendocrine tumors

Somatostatin and Somatostatin Receptors

Contact Info

Product

Resources

About